What the BPC-157 TB-500 GHK-Cu blend literature has measured
The BPC-157 TB-500 GHK-Cu blend combines three peptides that have each accumulated independent preclinical records across tissue repair, angiogenesis, and extracellular matrix remodeling. BPC-157 — a 15-amino-acid peptide derived from human gastric juice — has accelerated tendon, ligament, and wound healing in rodent studies through VEGFR2-mediated angiogenesis and nitric oxide signaling.[1][2][3] TB-500, the synthetic Ac-LKKTETQ fragment of thymosin beta-4, has promoted wound closure by 42–61% over saline controls in rat models and driven cell migration via G-actin sequestration.[9][10] GHK-Cu — glycyl-L-histidyl-L-lysine complexed with copper(II) — stimulates collagen synthesis in human fibroblast cultures at concentrations as low as 10−12 M and modulates approximately 4,000 human genes involved in repair and antioxidant defense.[14][15][16]
The three act at different points in the repair cascade: BPC-157 drives new vessel formation and fibroblast proliferation; TB-500 accelerates cell migration and reduces myofibroblast-driven scar formation; GHK-Cu remodels the extracellular matrix and restores collagen density. No peer-reviewed study has examined all three in co-administration. The combination rationale is mechanistic — three complementary pathways targeted simultaneously — not empirical co-administration data. This distinction is documented throughout this site.
Where the evidence thins
No peer-reviewed study has examined all three GLOW components in co-administration. Every synergy claim on this site is mechanistic rationale — each compound's individual pathway reasoning applied to the combination — not empirical co-administration data.
Fig. 01 / Three-peptide composition
Three pathways converging at a common root: angiogenesis (BPC-157), cell migration (TB-500), and extracellular matrix synthesis (GHK-Cu).